PackGene to Highlight AI-Driven Gene Therapy Innovations at ASGCT 2025

PackGene Biotech, Inc. will showcase its latest advancements in scalable AAV manufacturing and AI-driven capsid engineering at the American Society of Gene & Cell Therapy (ASGCT) 28th annual meeting in New Orleans from May 13-17, 2025. In a press release, the company announced six presentations highlighting its comprehensive suite of technology platforms and CDMO solutions aimed at accelerating gene therapy development and reducing costs.

Key presentations include a forum on advancing AAV manufacturing for affordable gene therapy and a poster session on targeted gene therapy using PackGene's π-Icosa Platform. The company will also discuss innovations in AAV production efficiency and capsid quantification, which are crucial for improving gene therapy affordability and effectiveness.

PackGene's integrated approach includes AI-assisted AAV capsid engineering, high-productivity vector manufacturing, and robust process analytics tools. These innovations are designed to address industry challenges such as vector tissue targeting, immunogenicity, safety, and manufacturability, supporting the company's mission to make gene therapy more accessible.